Patents Issued in October 12, 2017
-
Publication number: 20170291908Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U1, U2, U3, R1, R2, Z, and W are defined herein.Type: ApplicationFiled: April 11, 2017Publication date: October 12, 2017Inventors: Sanath Meegalla, Mark R. Player, Hui Huang, Michael P. Winters
-
Publication number: 20170291909Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.Type: ApplicationFiled: November 23, 2016Publication date: October 12, 2017Applicant: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
-
Publication number: 20170291910Abstract: The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.Type: ApplicationFiled: April 4, 2017Publication date: October 12, 2017Inventors: Rakesh Ishwar Patil, Jeevan Verma, Dharmesh Shah, Sazid Ali, Srinivasa Reddy Bapuram, Santosh Kumar Rai, Anil Kumar
-
Publication number: 20170291911Abstract: The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.Type: ApplicationFiled: April 12, 2017Publication date: October 12, 2017Inventors: Henry Joseph Breslin, Oren Gilad, Gerhard Sperl, Eric J. Brown, Laura Butler
-
Publication number: 20170291912Abstract: There is provided a process for preparing a zirconium-based metal organic framework (Zr-MOF), the process comprising the steps (i) preparing a reaction mixture comprising zirconium ions, sulfate ions and at least one organic linker compound in an aqueous solvent; and (ii) heating the reaction mixture from step (i).Type: ApplicationFiled: September 25, 2015Publication date: October 12, 2017Inventors: Helge Reinsch, Karl Peter Lillerud, Sachin Chavan, Unni Olsbye, Dirk De Vos, Norbert Stock
-
Publication number: 20170291913Abstract: A composition containing 2-propylheptyl silicate is obtained by heating ethyl silicate with an amount of 2-propylheptanol used in excess in the presence of titanium tetrabutoxide as catalyst to a temperature of not more than 220° C. while mixing, allowing them to react and, after the reaction, removing ethanol and excess 2-propylheptanol from the reaction mixture by distillation and obtaining the product, to obtain the composition comprising 2-propylheptyl silicate.Type: ApplicationFiled: April 11, 2017Publication date: October 12, 2017Applicant: Evonik Degussa GmbHInventors: Roland KRAFCZYK, Alexander KOEPFER, Stefanie MAYER, Burkhard STANDKE
-
Publication number: 20170291914Abstract: There is provided herein a polyalkylene-oxide-free surfactant composition comprising an ester-modified organosilicon having the general formula (I) AOaR4b(BOcR11d)e(C)fDg. There is also provided methods for making the ester-modified organosilicon (I) and agricultural, coating, personal care and home care applications containing the polyalkylene-oxide-free surfactant composition.Type: ApplicationFiled: April 7, 2016Publication date: October 12, 2017Inventors: George A. Policello, Narayan Mukherjee, Roland Wagner, Mark D. Leatherman
-
Publication number: 20170291915Abstract: Disclosed are Si-containing film forming compositions comprising carbosilane substituted amine precursors. The carbosilane substituted amine precursors have the formula (R1)aN(—SiHR2—CH2—SiH2R3)3-a, wherein a=0 or 1; R1 is H, a C1 to C6 alkyl group, or a halogen; R2 and R3 is each independently H; a halogen; an alkoxy group having the formula OR?, wherein R? is an alkyl group (C1 to C6); or an alkylamino group having the formula NR?2, wherein each R? is independently H, a C1-C6 alkyl group, a C1-C6 alkenyl group, or a C3-C10 aryl or heterocycle group. Also disclosed are methods of synthesizing the carbosilane substituted amine precursors and their use for deposition processes.Type: ApplicationFiled: September 23, 2015Publication date: October 12, 2017Inventors: Claudia FAFARD, Venkateswara R. PALLEM, Jean-Marc GIRARD
-
Publication number: 20170291916Abstract: Electrolyte solutions for flow batteries and other electrochemical systems can contain an active material capable of transferring more than one electron per oxidation-reduction cycle. Such active materials can include coordination compounds containing a metal center and at least one redox non-innocent ligand. Accordingly, flow batteries can include a first half-cell having a first electrolyte solution therein, where the first electrolyte solution contains a coordination compound having at least one redox non-innocent ligand coordinated to a metal center. Particular redox non-innocent ligands can include those bearing a quinone functional group, such as substituted catecholates bearing a quinone functional group. Some active materials can include compositions containing a coordination compound having at least one redox non-innocent ligand coordinated to a metal center, where the at least one redox non-innocent ligand is a substituted catecholate or a salt thereof bearing a quinone functional group.Type: ApplicationFiled: April 7, 2016Publication date: October 12, 2017Inventor: Matthew MILLARD
-
Publication number: 20170291917Abstract: There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Inventors: Matthew Colin Thor FYFE, Stephen Malcolm THOM
-
Publication number: 20170291918Abstract: Disclosed is a method for purifying a protein, comprising steps of: preparing a sample containing a fusion protein containing an amino acid sequence of a peptide tag and an amino acid sequence of a target protein; and separating contaminant proteins contained with the fusion protein in the sample and the fusion protein in the sample, wherein the peptide tag contains 12 or more acidic amino acid residues.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Applicant: SYSMEX CORPORATIONInventor: Ryo TAKAHASHI
-
Publication number: 20170291919Abstract: The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, and affinity chromatography matrices comprising such fusion proteins, as well as methods of using same.Type: ApplicationFiled: October 23, 2015Publication date: October 12, 2017Inventors: Martin Zillmann, Joe Orlando
-
Publication number: 20170291920Abstract: The present invention relates to nitric oxide donor carnosine derivatives having a great efficacy in reducing elevated intraocular pressure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.Type: ApplicationFiled: September 2, 2015Publication date: October 12, 2017Inventors: Nicoletta ALMIRANTE, Laura STORONI, Elena BASTIA, Stefania BRAMBILLA, Sergio ROMEO
-
Publication number: 20170291921Abstract: Provided is a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity, or a salt thereof.Type: ApplicationFiled: September 18, 2015Publication date: October 12, 2017Applicants: National University Corporation, Iwate University, Osaka City University, Iwate Medical University Educational Foundation, Lotte Co., Ltd.Inventors: Koichi SUZUKI, Shinichi ISHIGURO, Mayumi KARIMAZAWA, Makiko EBATA, Piyamas SILLAPAKONG, Takashi HIRAGA, Masaaki TSUSHIMA, Tetsuro SHINADA, Eiji NISHIMURA, Yasuo TERAYAMA, Hideyuki YASUDA
-
Publication number: 20170291922Abstract: Peptides effective as delta opioid receptor agonists and compositions comprising same are provided. Further provided are methods for targeting medical conditions amenable to treatment with an opioid receptor agonist, including but not limited to, conditions involving pain as well as reducing cocaine craving.Type: ApplicationFiled: April 10, 2017Publication date: October 12, 2017Inventors: Gal YADID, Michael FIRER, Rachela POPOVTZER
-
Publication number: 20170291923Abstract: Described are design and generation of a set of novel cyclic lipopeptides as potential antibacterial agents. New daptomycin analogues are generated by chemical synthesis, which makes introduction of an unnatural amino acid and any modification into daptomycin possible.Type: ApplicationFiled: April 8, 2016Publication date: October 12, 2017Inventor: Xuechen Li
-
Publication number: 20170291924Abstract: Disclosed are hypersensitive-response eliciting peptides and non-hypersensitive response eliciting peptides that induce active plant responses, and that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.Type: ApplicationFiled: March 31, 2017Publication date: October 12, 2017Inventors: Zhongmin WEI, Gregory A. ZORNETZER
-
Publication number: 20170291925Abstract: The present invention is directed to vegetative insecticidal proteins (Vips) modified to comprise heterologous carbohydrate binding modules and methods of use thereof.Type: ApplicationFiled: August 27, 2015Publication date: October 12, 2017Applicant: Syngenta Participations AGInventor: Joseph M. Watts
-
Publication number: 20170291926Abstract: The present invention discloses a method of preparing a functional peptide from a germinated bean, including the steps of: germinating a bean until a sprout length is about 0.5-1.0 cm; adding water to the obtained germinated bean, and then blending and crushing the germinated bean; adjusting the obtained slurry to a pH value between 6.5-8.0, and then adding neutral protease, papain and compound flavor protease to perform enzymatic reaction under stiffing condition, wherein an enzymatic reaction solution is obtained including the functional peptide; subjecting the enzymatic reaction solution to ultrafiltration using an ultrafiltration membrane; keeping the ultrafiltrated enzymatic reaction solution at a temperature between 70-80° C. or using ozonated water at a concentration between 20-25 mg/L thereby avoiding decomposition by microorganisms; and performing spray drying to obtain the functional peptide.Type: ApplicationFiled: January 11, 2017Publication date: October 12, 2017Inventors: Wei Wang, Nan Wang, Yu Zhang, Junhong Wang, Zuoyi Zhu, Xue Li, Jiahong Zhu
-
Publication number: 20170291927Abstract: The present invention relates to a gene that regulates BIN2 function and a transgenic plant into which the gene is introduced. When the gene of the present invention is introduced into an economically useful crop, it is advantageous to produce a high value-added plant with excellent productivity.Type: ApplicationFiled: March 27, 2017Publication date: October 12, 2017Inventors: Sunghwa CHOE, Yu Jeong JEONG
-
Publication number: 20170291928Abstract: Provided herein are chemical compounds, methods for their discovery, and their therapeutic and research use. Further provided herein are antiviral and antimicrobial lectin compounds and methods of their use.Type: ApplicationFiled: September 16, 2015Publication date: October 12, 2017Inventors: David M. MARKOVITZ, Jeanne A. STUCKEY, Daniel M. BOUDREAUX, Jennifer MEAGHER, Hashim AL-HASHIMI, Loic SALMON
-
Publication number: 20170291929Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.Type: ApplicationFiled: June 16, 2017Publication date: October 12, 2017Applicant: Amgen Inc.Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
-
Publication number: 20170291930Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiologica condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.Type: ApplicationFiled: April 11, 2017Publication date: October 12, 2017Applicants: University of Maryland, Baltimore, University of Maryland, College ParkInventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
-
Publication number: 20170291931Abstract: The present disclosure provides FGF2 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Thus, the disclosed mutant FGF2 proteins can be used to treat one or more metabolic diseases. In some examples, mutant FGF2 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels, for example to treat a metabolic disorder are also provided.Type: ApplicationFiled: June 8, 2017Publication date: October 12, 2017Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Jae Myoung Suh, Ruth T. Yu
-
Publication number: 20170291932Abstract: A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition.Type: ApplicationFiled: September 22, 2015Publication date: October 12, 2017Inventor: Fayez Safadi
-
Publication number: 20170291933Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.Type: ApplicationFiled: April 5, 2017Publication date: October 12, 2017Applicant: Acceleron Pharma, Inc.Inventors: Ravindra Kumar, John Knopf
-
Publication number: 20170291934Abstract: The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.Type: ApplicationFiled: September 21, 2015Publication date: October 12, 2017Inventors: CHARLES C. REED, GREGORY IAN FROST, JOAN MAZZARELLI SOPCZYNSKI, CHI ZHANG
-
Publication number: 20170291935Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.Type: ApplicationFiled: November 23, 2016Publication date: October 12, 2017Inventors: Matthew L. Sherman, Kenneth M. Attie
-
Publication number: 20170291936Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.Type: ApplicationFiled: June 15, 2017Publication date: October 12, 2017Inventor: Roland Beckmann
-
Publication number: 20170291937Abstract: The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3).Type: ApplicationFiled: April 7, 2017Publication date: October 12, 2017Inventors: Jesper Gromada, Viktoria Gusarova, Andrew J. Murphy
-
Publication number: 20170291938Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: ApplicationFiled: June 16, 2017Publication date: October 12, 2017Inventors: Gang CHEN, Darya BURAKOV, Dipali DESHPANDE
-
Publication number: 20170291939Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A and a peptide tag that binds hyaluronan (HA). The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.Type: ApplicationFiled: June 23, 2015Publication date: October 12, 2017Applicant: Novartis AGInventors: Franco E. DI PADOVA, Joy GHOSH, Thomas HUBER, Jean-Michel Rene RONDEAU
-
Publication number: 20170291940Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: November 23, 2016Publication date: October 12, 2017Inventors: David P. ARNOTT, Mercedes Z. BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
-
Publication number: 20170291941Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.Type: ApplicationFiled: June 19, 2017Publication date: October 12, 2017Inventors: Matthias Mack, Hilke Brühl, Kerstin Renner
-
Publication number: 20170291942Abstract: A method for treating depression or fatigue in a subject comprises administering an agent that blocks binding of IL-6 to IL-6 receptor, for example, an anti-IL-6 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of SEQ ID NO:99 and SEQ ID NO:97, respectively or a heavy chain variable region and a light chain variable region of SEQ ID NO:139 and SEQ ID NO:140, respectively. In addition, a method for determining responsiveness of an individual having depression to treatment with IL-6 antibody or antigen-binding fragment thereof, comprises: (a) measuring the amount of soluble IL-6 receptor (sIL-6R) in a biological sample from the subject; (b) providing a threshold value correlating the amount of sIL-6R and responsiveness; (c) comparing the amount of sIL-6R to the threshold value to determine responsiveness; and (d) treating the individual with an agent that blocks binding of IL-6 to IL-6 receptor.Type: ApplicationFiled: April 6, 2017Publication date: October 12, 2017Inventors: Guang Chen, Yu Sun, Dai Wang, Gayle Wittenberg
-
Publication number: 20170291943Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFN?), thereby modulating the interaction between IFN? and its receptor, IFN?-R, and/or modulating the biological activities of IFN?. The invention also relates to the use of such anti-IFN? antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.Type: ApplicationFiled: June 20, 2017Publication date: October 12, 2017Inventors: Walter Ferlin, Nicolas Fischer, Greg Elson, Olivier Leger
-
Publication number: 20170291944Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.Type: ApplicationFiled: April 20, 2017Publication date: October 12, 2017Applicant: Research Development FoundationInventors: Beat IMHOF, Christiane ODY, Thomas MATTHES, Carmen DONATE
-
Publication number: 20170291945Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.Type: ApplicationFiled: September 9, 2015Publication date: October 12, 2017Inventors: Nicholas J. Leeper, Irving L. Weissman
-
Publication number: 20170291946Abstract: Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein such as an antibody or antigen binding fragment thereof.Type: ApplicationFiled: September 28, 2015Publication date: October 12, 2017Applicant: The Regents of the University of CaliforniaInventors: Matthew Krummel, Miranda Broz, Denise Wolf, Joshua Pollack, Mikhail Biennewies
-
Publication number: 20170291947Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.Type: ApplicationFiled: September 15, 2015Publication date: October 12, 2017Inventors: PASCALE ANDRE, MATHIEU BLERY, CARINE PATUREL, NICOLAI WAGTMANN
-
Publication number: 20170291948Abstract: The present disclosure relates to an antibody binding to Neuropilin 1 (NRP1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a composition thereof for preventing or treating a cancer.Type: ApplicationFiled: December 3, 2015Publication date: October 12, 2017Inventors: Do-Hyun Nam, Yeup Yoon, Jae Hyun Lee, Jin Ku Lee
-
Publication number: 20170291949Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: ApplicationFiled: April 8, 2016Publication date: October 12, 2017Applicant: Sorrento Therapeutics, Inc.Inventor: Heyue Zhou
-
Publication number: 20170291950Abstract: The invention is directed to a method of treating multiloculated hydrocephalus comprising administering to a subject who is suffering from multiloculated hydrocephalus an antibody that binds to an IL-6 receptor.Type: ApplicationFiled: April 10, 2017Publication date: October 12, 2017Applicant: IMAM ABDULRAHMAN BIN FAISAL UNIVERSITYInventors: Fatima AbdulRahim FAKHROO, Ahmed Ammar
-
Publication number: 20170291951Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.Type: ApplicationFiled: January 13, 2015Publication date: October 12, 2017Applicant: KYMAB LIMITEDInventors: Jamie Iain CAMPBELL, Bettina FRANZ, Steve HOLMES, Ian KIRBY, Anais LEGENT
-
Publication number: 20170291952Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: ApplicationFiled: April 6, 2016Publication date: October 12, 2017Inventors: Svetomir N. MARKOVIC, Wendy K. NEVALA
-
Publication number: 20170291953Abstract: An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.Type: ApplicationFiled: October 6, 2015Publication date: October 12, 2017Applicant: YAMAGUCHI UNIVERSITYInventors: Koji TAMADA, Yukimi SAKODA, Keishi ADACHI
-
Publication number: 20170291954Abstract: The present invention relates to compositions and methods of isolated polynucleotides that encode or polypeptides comprising glypican-3 (GPC3). The invention also includes a chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. The invention further includes methods of treating a subject or diagnosing and treating diseases, disorders or conditions associated with dysregulated glypican-3.Type: ApplicationFiled: September 3, 2015Publication date: October 12, 2017Inventor: David KAPLAN
-
Publication number: 20170291955Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.Type: ApplicationFiled: April 10, 2015Publication date: October 12, 2017Inventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
-
Publication number: 20170291956Abstract: Methods of treatment of cancer are provided. In particular, methods of treatment of low-grade serous ovarian cancers by inhibiting signaling of an EGFR family member are provided.Type: ApplicationFiled: July 15, 2015Publication date: October 12, 2017Inventors: David Livingston, Joyce Liu, Ronny Drapkin
-
Publication number: 20170291957Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: November 8, 2016Publication date: October 12, 2017Inventors: Victor MOYO, Gabriela GARCIA